With de­layed re­view date loom­ing, Bris­tol My­ers un­corks more win­ning da­ta for block­buster-po­ten­tial heart drug

Bris­tol My­ers Squibb doled out a whop­ping $13 bil­lion for MyoKar­dia back in late 2020, main­ly on the block­buster hopes of heart drug mava­camten. De­spite some win­ning late-stage da­ta, the drug has seen noth­ing but de­lays — but an­oth­er big win could put some wind in Bris­tol My­ers’ sails as a key re­view date ap­proach­es.

On Wednes­day, Bris­tol My­ers re­vealed topline da­ta from the Phase III VAL­OR-HCM tri­al show­ing mava­camten best­ed place­bo in re­duc­ing the need for an in­va­sive pro­ce­dure in pa­tients with ob­struc­tive hy­per­trophic car­diomy­opa­thy (oHCM), the drug gi­ant said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER